GlaxoSmithKline (GSK) Receives $42.00 Average PT from Analysts

Shares of GlaxoSmithKline (NYSE:GSK) have been assigned an average rating of “Hold” from the seventeen research firms that are currently covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating, ten have given a hold rating and five have issued a buy rating on the company. The average 1-year target price among analysts that have issued a report on the stock in the last year is $40.00.

GSK has been the subject of several analyst reports. Kepler Capital Markets raised shares of GlaxoSmithKline from a “reduce” rating to a “hold” rating in a report on Friday, February 9th. Zacks Investment Research cut shares of GlaxoSmithKline from a “buy” rating to a “hold” rating in a report on Wednesday, January 10th. Cowen reissued a “hold” rating and set a $40.00 price target on shares of GlaxoSmithKline in a report on Thursday, February 15th. ValuEngine cut shares of GlaxoSmithKline from a “buy” rating to a “hold” rating in a report on Friday, February 2nd. Finally, JPMorgan Chase reissued a “neutral” rating on shares of GlaxoSmithKline in a report on Thursday, January 11th.

How to Become a New Pot Stock Millionaire

Shares of NYSE:GSK traded up $0.12 on Friday, reaching $40.00. The company’s stock had a trading volume of 2,924,227 shares, compared to its average volume of 3,465,769. GlaxoSmithKline has a 52-week low of $34.52 and a 52-week high of $44.53. The company has a debt-to-equity ratio of 4.09, a quick ratio of 0.39 and a current ratio of 0.60. The stock has a market capitalization of $99,177.36, a price-to-earnings ratio of 13.89, a PEG ratio of 2.13 and a beta of 0.84.



GlaxoSmithKline (NYSE:GSK) last announced its earnings results on Wednesday, February 7th. The pharmaceutical company reported $0.72 EPS for the quarter, beating analysts’ consensus estimates of $0.69 by $0.03. GlaxoSmithKline had a net margin of 4.97% and a return on equity of 130.63%. The business had revenue of $10.14 billion during the quarter, compared to analysts’ expectations of $9.89 billion. research analysts forecast that GlaxoSmithKline will post 2.92 EPS for the current fiscal year.

The company also recently declared a quarterly dividend, which was paid on Thursday, April 12th. Investors of record on Friday, February 23rd were issued a dividend of $0.633 per share. This is a boost from GlaxoSmithKline’s previous quarterly dividend of $0.50. This represents a $2.53 annualized dividend and a yield of 6.33%. The ex-dividend date was Thursday, February 22nd. GlaxoSmithKline’s dividend payout ratio is currently 89.93%.

A number of institutional investors and hedge funds have recently modified their holdings of the business. Profund Advisors LLC grew its position in GlaxoSmithKline by 3.0% during the fourth quarter. Profund Advisors LLC now owns 52,264 shares of the pharmaceutical company’s stock worth $1,854,000 after buying an additional 1,519 shares during the period. Atria Investments LLC grew its position in GlaxoSmithKline by 17.1% during the fourth quarter. Atria Investments LLC now owns 12,830 shares of the pharmaceutical company’s stock worth $455,000 after buying an additional 1,874 shares during the period. Canandaigua National Bank & Trust Co. grew its position in GlaxoSmithKline by 14.6% during the fourth quarter. Canandaigua National Bank & Trust Co. now owns 15,297 shares of the pharmaceutical company’s stock worth $543,000 after buying an additional 1,950 shares during the period. Hoertkorn Richard Charles grew its position in GlaxoSmithKline by 4.5% during the fourth quarter. Hoertkorn Richard Charles now owns 48,075 shares of the pharmaceutical company’s stock worth $1,705,000 after buying an additional 2,050 shares during the period. Finally, IFC Holdings Incorporated FL grew its position in shares of GlaxoSmithKline by 15.2% in the fourth quarter. IFC Holdings Incorporated FL now owns 15,744 shares of the pharmaceutical company’s stock valued at $560,000 after purchasing an additional 2,079 shares during the last quarter. Institutional investors own 10.96% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This article was originally reported by StockNewsTimes and is owned by of StockNewsTimes. If you are accessing this article on another website, it was illegally copied and republished in violation of U.S. and international copyright and trademark law. The original version of this article can be accessed at https://stocknewstimes.com/2018/04/22/glaxosmithkline-gsk-receives-42-00-average-pt-from-analysts.html.

About GlaxoSmithKline

GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of vaccines, over-the-counter medicines, and health-related consumer products worldwide. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, dermatology, rare diseases, immuno-inflammation, and HIV, as well as vaccines.

Analyst Recommendations for GlaxoSmithKline (NYSE:GSK)

Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply